Journal article
Selective digestive tract decontamination in critically ill adults with acute brain injuries: a post hoc analysis of a randomized clinical trial
PJ Young, A Devaux, Q Li, L Billot, JS Davis, A Delaney, SR Finfer, NE Hammond, S Micallef, IM Seppelt, B Venkatesh, JA Myburgh, A Gordon, B Cuthbertson, R Fowler, S Murthy, N Pattison, J Iredell, C Taylor, D Young Show all
Intensive Care Medicine | Published : 2024
Abstract
Purpose: The aim of this study was to determine whether selective decontamination of the digestive tract (SDD) reduces in-hospital mortality in mechanically ventilated critically ill adults admitted to the intensive care unit (ICU) with acute brain injuries or conditions. Methods: We carried out a post hoc analysis from a crossover, cluster randomized clinical trial. ICUs were randomly assigned to adopt or not to adopt a SDD strategy for two alternating 12-month periods, separated by a 3-month inter-period gap. Patients in the SDD group (n = 2791; 968 admitted to the ICU with an acute brain injury) received a 6-hourly application of an oral paste and administration of a gastric suspension co..
View full abstractGrants
Awarded by Health Research Council of New Zealand
Funding Acknowledgements
No specific funding for this post hoc analysis was obtained. The SuDDICU Australia trial was supported by a Project Grant from the National Health and Medical Research Council of Australia (Project Grant number 1084244); by a Leadership Fellowship from National Health and Medical Research Council of Australia (to JAM); by Practitioner Fellowships from the National Health and Medical Research Council of Australia (to SRF); by a Career Development Fellowship from National Health and Medical Research Council (to JSD); by an Emerging Leader Investigator Grant from the National Health and Medical Research Council of Australia (to NEH); by a Clinical Practitioner Research Fellowship from the Health Research Council of New Zealand (to PJY). The George Institute for Global Health, Australia was the Principal Sponsor for this trial. SDD drug preparations were purchased and manufactured under contract with the George Institute for Global Health by Verita Pharma (R) (Sydney, Australia). The sponsor, funders and drug manufacturer had no input into the design and conduct of the study, collection, management, analysis and interpretation of data; preparation, review or approval of the manuscript; and the decision to submit the manuscript for publication. The Sponsor had no right of veto to publish this trial or to control the decision regarding to which journal the paper was submitted.